One SIRT-6 inhibitor with quinazolinedione structure (named compound 1 and identified via in silico screening, see Section 3.6) [174] was administered following both a “preventive” and a “therapeutic” protocol in a mouse model of Experimental Autoimmune Encephalomyelitis (EAE), regarded as an MS animal model. Here, SIRT6 is linked to myeloid sarcoma.